These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34225439)

  • 21. [Immunotherapy clinical application and research prospects for liver cancer].
    Xia F; Chen XP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):615-617. PubMed ID: 34371529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist.
    Winters AC; Bedier F; Saab S
    Clin Liver Dis; 2020 Nov; 24(4):755-769. PubMed ID: 33012457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
    Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Kudo M
    Oncology; 2017; 92 Suppl 1():50-62. PubMed ID: 28147363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
    Vardhana S; Cicero K; Velez MJ; Moskowitz CH
    Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
    Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
    BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?
    Rizzo A
    Expert Opin Investig Drugs; 2022 Apr; 31(4):333-335. PubMed ID: 34176423
    [No Abstract]   [Full Text] [Related]  

  • 31. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma.
    Lee BM; Seong J
    World J Gastroenterol; 2021 Mar; 27(10):919-927. PubMed ID: 33776363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in older patients with hepatocellular carcinoma.
    Lyu N; Yi JZ; Zhao M
    Eur J Cancer; 2022 Feb; 162():76-98. PubMed ID: 34954439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis.
    Yuan H; Mao J; Liu C; Fu H; Guo W; Ding G
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):845-854. PubMed ID: 32307332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors.
    Bertaglia V; Petrelli F; Porcu M; Saba L; Pearce J; Luciani A; Solinas C; Scartozzi M
    Cytokine Growth Factor Rev; 2022 Oct; 67():1-10. PubMed ID: 35945096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
    Yao X; Wang L; Gao J
    Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
    Woo HY; Yoo SY; Heo J
    Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
    Morse MA; Hochster H; Benson A
    Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.